Lazard Asset Management
MCRB icon

Lazard Asset Management’s Seres Therapeutics MCRB Stock Holding History

Lazard Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-414
Closed -$68K – 2445
2021
Q4 		$68K Buy
+414
New +$65.8K ﹤0.01% 1601
2019
Q4 		– Sell
-261
Closed -$20K – 1607
2019
Q3 		$20K Buy
+261
New +$17.2K ﹤0.01% 1078

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Lazard Asset Management's MCRB Position: Q1 2022 in Review

Lazard Asset Management sold out of Seres Therapeutics (MCRB) in Q1 2022, closing a stake of 414 shares — an estimated $68K sold.

Lazard Asset Management first reported a position in MCRB in Q3 2019 and held it in 2 quarters. The position peaked at $68K in Q4 2021. 131 funds tracked by Wall St. Rank hold MCRB as of Q1 2022.

  • Lazard Asset Management reported no remaining Seres Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Lazard Asset Management sold 414 Seres Therapeutics shares in Q1 2022, an estimated $68K.
  • Lazard Asset Management first reported a position in Seres Therapeutics in Q3 2019 and held it in 2 quarters.
  • Lazard Asset Management's Seres Therapeutics position peaked at $68K in Q4 2021.
  • 131 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2022.

Based on Lazard Asset Management's 13F filing for Q1 2022, filed 13 May 2022.